Lasofoxifene treatment of aromatase-resistant er+ cancer

TW202635291APending Publication Date: 2026-09-01SERMONIX PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW115120010
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-18
Filing Date
2022-11-17
Publication Date
2026-09-01

Smart Images

  • Figure TWG2TA001075431_001
    Figure TWG2TA001075431_001
  • Figure TWG2TA001075431_002
    Figure TWG2TA001075431_002
  • Figure TWG2TA001075431_003
    Figure TWG2TA001075431_003
Patent Text Reader

Abstract

The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in a patient who has progressed on an aromatase inhibitor. Of particular interest are ER+ cancers that do not harbor a gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor
Need to check novelty before this filing date? Find Prior Art